We are live on ! Find out more
RVPHW

Reviva Pharmaceuticals Warrants
RVPHW

Delisted

RVPHW was delisted on the 12th of December, 2025.

Back to rankings

8 hedge funds and large institutions have $1.48M invested in Reviva Pharmaceuticals Warrants in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

20% less funds holding

Funds holding: 10 → 8 (-2)

34% less capital invested

Capital invested by funds: $2.26M → $1.48M (-$777K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
8
Holders Change
-2
Holders Change %
-20%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$901
2
UBS Group
UBS Group
Switzerland
+$27

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$244K
2
6CM
683 Capital Management
New York
-$102K
3
ICM
Ionic Capital Management
New York
-$69K
4
AA
AQR Arbitrage
Connecticut
-$25.1K

RVPHW Hedge Fund Activity: Q3 2021 in Review

8 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q3 2021, worth a combined $1.48M — down 34% from $2.26M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of RVPHW and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $901. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $244K sold.

  • 8 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q3 2021, down from 10 in Q2 2021.
  • Funds reported $1.48M of Reviva Pharmaceuticals Warrants stock for Q3 2021, down 34% quarter-over-quarter.
  • 1 fund opened new Reviva Pharmaceuticals Warrants positions in Q3 2021 and 3 closed out, a net change of -2 holders.
  • The largest Reviva Pharmaceuticals Warrants buyer in Q3 2021 was Wolverine Asset Management, an estimated $901 added.
  • The largest Reviva Pharmaceuticals Warrants seller in Q3 2021 was Glazer Capital LLC, an estimated $244K sold.

Based on aggregated 13F filings for Q3 2021.